Breakthroughs Blog

Breakthroughs brings you stories of bright ideas and bold innovations in global health.

The Latest
Ansley Kahn
Research Roundup: FDA advisory panel recommends approval of TB Alliance's TB treatment, innovation in women's health, and British syringe-free vaccine maker set to shake up the industry

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Recent

PATH/Evelyn Hockstein
Research Roundup: Drug development costs, the price of priority review, new clinical trial requirements, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
Ten global health advancements I’m thankful for this Thanksgiving

As global health advocates, our work often requires us to focus on unmet needs—such as the number of people worldwide who still die from preventable diseases each year, or the lack of adequate resources and investment to tackle these diseases.

Read More
PATH/Eric Becker
Research Roundup: Malaria eradication, indemnity for Ebola vaccine manufacturers, drug development impediments, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
#CoughUpTheTBMoney: TB activists call for tripling annual spending on TB research

In this guest post, Mike Watson Frick—TB/HIV program officer at Treatment Action Group (TAG)—writes about the state of tuberculosis (TB) research funding and civil society actions that took place at the recent Union World Conference on Lung Health in Barcelona, Spain.

Read More
Election results are in: Here’s what happened and how it could impact global health R&D

Election night saw an historic shift in Congress, with Republicans extending their majority in the House of Representatives and capturing the Senate for the first time since 2006.

GHTC
Read More
Research Roundup: Midterm elections, Ebola legislation, HIV prevention research, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

Read More
How the upcoming election could impact global health R&D

As candidates make their final pitches, volunteers canvas like crazy, and pollsters make their predictions, GHTC is taking a look at what the outcomes of next week’s election could mean for global health research and development (R&D).

GHTC
Read More
HIV Vaccines and Microbicides Resource Tracking Working Group
First-ever conference devoted solely to HIV prevention R&D taking place in uncertain funding environment

Progress toward new tools to prevent HIV infection—including vaccines, microbicides, the use of antiretroviral treatment as HIV prevention, pre-exposure prophylaxis (PrEP), and a host of other options—is being presented and discussed at the inaugural HIV Research for Prevention Conference (HIVR4P) in Cape Town this week.

AVAC
Read More
FDA/Michael J. Ermarth
Four reasons you should check out the Global Health Regulatory Requirements Database

Navigating global regulatory processes is a critical component to the development and introduction of global health technologies.

PATH
Read More
PATH/Evelyn Hockstein
Research Roundup: Ebola vaccine hurdles, SDG financing, blocking malaria transmission, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
PATH/Aaron Joel Santos
Research Roundup: hookworm vaccine trial, Grand Challenges turns ten, NIH funding for Ebola and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
PATH/Heng Chivoan
Research Roundup: Intellectual property awards, FDA priorities, Australia R&D, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
PATH/Satvir Malhotra
Research Roundup: R&D in the post-2015 agenda, TB vaccines, the Global Innovation Fund, intellectual property, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
Making the case for research and innovation for health in the post-2015 development agenda

In this guest post, Claire Wingfield—product development policy officer at PATH—writes about a new paper exploring why research and development (R&D) of high-priority health tools for diseases and conditions affecting low- and middle-income countries (LMICs) should be a critical component of the post-2015 development agenda.

PATH
Read More
PATH
Research Roundup: UNGA, public-private partnerships, new executive orders, neglected disease R&D grants, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
Over 150 organizations and individuals urge UN to keep health R&D at the heart of the post-2015 agenda

With the 69th session of the United Nations (UN) General Assembly opening this week in New York and the global community debating how best to refine the post-2015 development agenda, over 150 organizations and individuals signed a petition to UN Secretary General Ban Ki-moon and Member States urging the UN to keep the research, development, and delivery of new and improved health tools at the heart of the post-2015 development agenda.

Read More
Research Roundup: Congressional priorities, new HIV antibody, biomedical research funding, TB drug trial results, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
Recess is over: What Congress should act on now

After a five week recess, members of Congress returned to their Capitol Hill offices on Tuesday night.

GHTC
Read More
PATH/Dan Chang
Research Roundup: Funding global health R&D, the neglected disease pipeline, Ebola vaccines, FDA approvals, and more

In this regular feature on Breakthroughs, we highlight some of the most interesting reads in global health research from the past week.

GHTC
Read More
Why invest in R&D for HIV, TB and malaria? Because it’s good for global health, and good for Europe

In this post, Eoghan Walsh—communications officer at Deutsche Stiftung Weltbevoelkerung (DSW)—writes about the need for Europe to increase financial and political support for efforts aimed at creating new ways to tackle diseases such as HIV/AIDS, tuberculosis (TB) and malaria.

Read More